BOTHELL, WA and VANCOUVER, British Columbia, June 28, 2011 /CNW/ -
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), a biopharmaceutical
company committed to the development and commercialization of new
cancer therapies that address treatment resistance in cancer patients,
announced today that the Company was added to the Russell Global Index,
Russell 2000® Index, Russell 3000® Index and Russell Microcap® Index at
the close of market on June 24, 2011 as part of the annual
reconstitution of Russell indexes.
Annual reconstitution of Russell's U.S. indexes captures and ranks the
4,000 largest U.S. stocks as of the end of May. Russell indexes are
widely used by investment managers and institutional investors for
index funds and as benchmarks for both passive and active investment
strategies. An industry-leading $3.9 trillion in institutional assets
currently are benchmarked to them.
Russell determines membership for its equity indexes primarily by
objective, market-capitalization rankings and style attributes. The
Russell Global Index, which captures 98% of investable securities
globally, is reconstituted annually and all sub-indexes are
recalibrated simultaneously to accurately measure current market
realities for each market segment. The Russell 2000 Index measures the
performance of the small-cap segment of the U.S. equity universe. The
Russell 2000 Index is a subset of the Russell 3000 Index representing
approximately 10% of the total market capitalization of that index. The
Russell 2000 is constructed to provide a comprehensive and unbiased
small-cap barometer. The Russell 3000 Index is constructed to provide a
comprehensive, unbiased, and stable barometer of the broad market.
Membership in the Russell Microcap Index means automatic inclusion in
the appropriate growth and value style indexes.
More information about Russell indexes, including total returns, is
available at http://www.russell.com/Indexes/data/default.asp.
About OncoGenex Pharmaceuticals
OncoGenex is a biopharmaceutical company committed to the development
and commercialization of new cancer therapies that address treatment
resistance in cancer patients. OncoGenex has a diverse oncology
pipeline, with each product candidate having a distinct mechanism of
action and representing a unique opportunity for cancer drug
development. OncoGenex and Teva Pharmaceutical Industries Ltd. have
entered a global collaboration and license agreement to develop and
commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is
currently in Phase 3 clinical development as a treatment in men with
metastatic castrate-resistant prostate cancer. The companies plan to
begin Phase 3 development of custirsen in first-line treatment of
advanced, unresectable non-small cell lung cancer in 2011. OGX-427 is
in Phase 2 clinical development; and CSP-9222 and OGX-225 are currently
in pre-clinical development. More information on OncoGenex can be found
SOURCE OncoGenex Pharmaceuticals, Inc.
For further information: